Program
Lamivudine
Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 352 open or running | phase 4since Feb 15, 2000 | Nov 2, 1999 | Sep 14, 2032phase 3 · NCT07393659 |
| Bristol-Myers Squibb | 70 open or running | phase 4since Jun 27, 2005 | Nov 2, 1999 | none ahead |
| Abbott | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Dupont Merck | 20 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| triangle-pharmaceuticals | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
Also a collaborator on its studies: ppd-development-lp and dupont-applied-biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 33 studies since Nov 2, 1999.
- Jun 13, 2012Phase 3 study in HIVBristol-Myers Squibb · NCT01620944 · 3 enrolled
- Jul 25, 2013Phase 3 study in InfectionsGlaxoSmithKline · NCT01910402 · 499 enrolled · United States, Argentina, Canada and more
- Apr 3, 2014Phase 3 study in InfectionsGlaxoSmithKline · NCT02105987 · 555 enrolled · United States, Canada, Puerto Rico
- Dec 14, 2015Phase 4 study in InfectionsGlaxoSmithKline · NCT02634073 · 16 enrolled · United States
- Apr 11, 2016Phase 1 study in InfectionsGlaxoSmithKline · NCT02738931 · 30 enrolled · United States
- Jul 8, 20162 phase 3 studies in InfectionsGlaxoSmithKline · NCT02831764, NCT02831673
- Mar 8, 2017Phase 1 study in InfectionsGlaxoSmithKline · NCT03078556 · 154 enrolled · United States
- Jan 5, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03446573 · 743 enrolled · United States, Australia, Belgium and more
- Sep 21, 2018Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03682848 · 32 enrolled · Kenya, South Africa, Thailand
- May 8, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT03945981 · 131 enrolled · United States
- Jul 11, 2019Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT04021290 · 493 enrolled · United States, Argentina, Belgium and more
- Jun 9, 20232 phase 3 studies in HIV InfectionsGlaxoSmithKline · NCT05911360, NCT05917509
- Jul 19, 2023Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT05979311 · 463 enrolled · Argentina, Belgium, Denmark and more
- Jan 30, 2026Phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659 · 197 planned · Romania, South Africa, Uganda
Ahead
- Sep 14, 2032Primary completion: phase 3 study in HIV InfectionsGlaxoSmithKline · NCT07393659
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 49 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07393659HIV Infections · Romania, South Africa, Uganda | 3 | Recruiting | GlaxoSmithKline | Sep 14, 2032 | 197 |
| NCT05979311HIV Infections · Argentina, Belgium, Denmark and more | 3 | Active, not recruiting | GlaxoSmithKline | Apr 15, 2026 | 463 |
| NCT05917509HIV Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 16, 2025 | 171 |
| NCT05911360HIV Infections · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | Jan 23, 2026 | 205 |
| NCT04021290HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | GlaxoSmithKline | Apr 23, 2021 | 493 |
| NCT03945981HIV Infections · United States | 3 | Completed | GlaxoSmithKline | Apr 29, 2020 | 131 |
| NCT03682848HIV Infections · Kenya, South Africa, Thailand | 3 | Completed | GlaxoSmithKline | Dec 1, 2021 | 32 |
| NCT03446573HIV Infections · United States, Australia, Belgium and more | 3 | Completed | GlaxoSmithKline | May 20, 2019 | 743 |
| NCT03078556Infections · United States | 1 | Completed | GlaxoSmithKline | Aug 18, 2017 | 154 |
| NCT02831764Infections · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Apr 4, 2018 | 722 |
| NCT02831673Infections · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Mar 29, 2018 | 719 |
| NCT02738931Infections · United States | 1 | Completed | GlaxoSmithKline | Jun 2016 | 30 |
| NCT02634073Infections · United States | 4 | Completed | GlaxoSmithKline | Mar 1, 2016 | 16 |
| NCT02105987Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | Apr 2015 | 555 |
| NCT01910402Infections · United States, Argentina, Canada and more | 3 | Completed | GlaxoSmithKline | Sep 22, 2015 | 499 |
| NCT01620944HIV | 3 | Terminated | Bristol-Myers Squibb | Jan 22, 2013 | 3 |
| NCT00549198Infections · Austria, Belgium, Denmark and more | 4 | Completed | GlaxoSmithKline | Dec 2009 | 392 |
| NCT00440947Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | Jul 2010 | 515 |
| NCT00410202Hepatitis B, Chronic · United States, Australia, Brazil and more | 3 | Completed | Bristol-Myers Squibb | Jan 2011 | 629 |
| NCT00354653Hepatitis B, Chronic · Iran, Islamic Republic of | 4 | Completed | GlaxoSmithKline | Jan 23, 2007 | 100 |
| NCT00337922HIV Infections · Japan | 4 | Completed | GlaxoSmithKline | 8 | |
| NCT00234923HIV Infections | 3 | Completed | Abbott | Feb 2007 | 138 |
| NCT00140725Hepatitis B, Chronic · Hong Kong | 3 | Completed | GlaxoSmithKline | 160 | |
| NCT00135369HIV Infections · United States, Puerto Rico | 3 | Completed | Bristol-Myers Squibb | Jul 2005 | 300 |
| NCT00116298HIV Infections · United States, Argentina, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Jan 2005 | 900 |
| NCT00116116HIV Infections · United States | 4 | Completed | Bristol-Myers Squibb | Jun 2005 | 70 |
| NCT00085943HIV Infections · United States, Austria, Belgium and more | 3 | Completed | GlaxoSmithKline | 866 | |
| NCT00046176Infections · United States, Costa Rica, Panama and more | 3 | Completed | GlaxoSmithKline | May 17, 2004 | 240 |
| NCT00043953HIV Infections · United States, Canada | 2 | Completed | Abbott | 30 | |
| NCT00038220HIV Infections · United States | 2 | Completed | Abbott | 40 | |
| NCT00013897HIV Infections · United States, Austria, Belgium and more | 3 | Completed | Bristol-Myers Squibb | Apr 2003 | |
| NCT00011895HIV Infections · United States | 4 | UNKNOWN | GlaxoSmithKline | 400 | |
| NCT00009061HIV Infections · United States | 3 | UNKNOWN | GlaxoSmithKline | 624 | |
| NCT00005106HIV Infections · United States | 4 | Completed | GlaxoSmithKline | 230 | |
| NCT00004981HIV Infections · United States | 3 | UNKNOWN | GlaxoSmithKline | 230 | |
| NCT00004852HIV Infections · United States, Argentina, Brazil and more | 2 | Completed | GlaxoSmithKline | ||
| NCT00004585HIV Infections · United States | 4 | Completed | GlaxoSmithKline | 40 | |
| NCT00004583HIV Infections · United States, Australia, Austria and more | 3 | Completed | Abbott | 660 | |
| NCT00002442HIV Infections · United States | 2 | Completed | GlaxoSmithKline | ||
| NCT00002436HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | 325 | |
| NCT00002416HIV Infections · United States | 3 | Completed | triangle-pharmaceuticals | 390 | |
| NCT00002410HIV Infections · United States, Puerto Rico | 3 | Completed | Dupont Merck | ||
| NCT00002409HIV Infections · United States | 3 | Completed | GlaxoSmithKline | 200 | |
| NCT00002391HIV Infections · United States | 3 | Completed | GlaxoSmithKline | ||
| NCT00002389HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | 210 | |
| NCT00002371HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | Bristol-Myers Squibb | Dec 1997 | 80 |
| NCT00002320HIV Infections · United States, Canada, Puerto Rico | 3 | Completed | GlaxoSmithKline | 320 | |
| NCT00002227HIV Infections · United States | 2 | Completed | Dupont Merck | 60 | |
| NCT00002108HIV Infections · United States | – | Completed | GlaxoSmithKline |
How it is read
Names in the registry
- “Lamivudine”, 35 entries
- “Lamivudine/Zidovudine”, 6 entries
- “Lamivudine (3TC)”, 4 entries
- “lamivudine”, 3 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 53 studies
- Acquired Immunodeficiency Syndrome, 8 studies
- Hepatitis B, Chronic, 6 studies
- Infections, 4 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.